文献速递系统性红斑狼疮

系统性红斑狼疮诊断与管理进展

Update οn the diagnosis and management of systemic lupus erythematosus.
PubMed 文献 · Ann Rheum Dis · 2020-10-13

综述指出SLE临床异质性强、病程不可预测,诊断仍以临床为主,EULAR/ACR 2019分类标准有助于更早更准确分类;约70%患者呈复发缓解病程,治疗目标包括长期生存、预防复发和器官损害,新型改善病情药物可提高达标率并减少糖皮质激素使用。

要点

  • EULAR/ACR 2019分类标准有助于SLE更早、更准确分类,但分类标准用于诊断需谨慎。
  • 约70%SLE患者呈复发缓解病程,近半数轻症患者随时间进展为更严重疾病。
  • 器官威胁或生命威胁性SLE采用先高强度免疫抑制后低强度巩固治疗策略。

核心结论

  • SLE诊断仍以临床为主,EULAR/ACR 2019分类标准可更早更准确分类,但分类标准用于诊断存在明显局限。
  • 治疗目标包括长期生存、预防复发和器官损害、优化健康相关生活质量,新型改善病情药物可提高短期和长期达标率并减少糖皮质激素使用。

研究设计与样本

  • 本文为综述,汇总SLE诊断与管理进展,未报告系统检索范围。

主要发现

  • SLE临床异质性强、病程不可预测且易复发,偶可呈器官主导型而带来诊断挑战。
  • 部分病例血清学检测阴性,诊断仍依赖临床。
  • 近年来识别出多种疾病内型,轻症初诊者增多但近半数随时间进展为更严重疾病。
  • 约70%患者呈复发缓解病程,其余均分为长期缓解与持续活动性疾病。

关键数值与推荐

  • EULAR/ACR 2019分类标准有助于更早、更准确分类SLE。

临床怎么用

  • 对器官威胁或生命威胁性SLE,先高强度免疫抑制控制活动,后较长周期低强度治疗巩固应答并预防复发。
  • 管理疾病相关和治疗相关合并症,尤其感染和动脉粥样硬化,至关重要。
  • 新型传统和生物改善病情药物可单用、联用或序贯使用,以提高短期和长期治疗目标达标率并减少糖皮质激素使用。

局限性

  • 本文为综述,未报告系统检索策略与纳入研究数量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical heterogeneity, unpredictable course and flares are characteristics of systemic lupus erythematosus (SLE). Although SLE is-by and large-a systemic disease, occasionally it can be organ-dominant, posing diagnostic challenges. To date, diagnosis of SLE remains clinical with a few cases being negative for serologic tests. Diagnostic criteria are not available and classification criteria are often used for diagnosis, yet with significant caveats. Newer sets of criteria (European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) 2019) enable earlier and more accurate classification of SLE. Several disease endotypes have been recognised over the years. There is increased recognition of milder cases at presentation, but almost half of them progress overtime to more severe disease. Approximately 70% of patients follow a relapsing-remitting course, the remaining divided equally between a prolonged remission and a persistently active disease. Treatment goals include long-term patient survival, prevention of flares and organ damage, and optimisation of health-related quality of life. For organ-threatening or life-threatening SLE, treatment usually includes an initial period of high-intensity immunosuppressive therapy to control disease activity, followed by a longer period of less intensive therapy to consolidate response and prevent relapses. Management of disease-related and treatment-related comorbidities, especially infections and atherosclerosis, is of paramount importance. New disease-modifying conventional and biologic agents-used alone, in combination or sequentially-have improved rates of achieving both short-term and long-term treatment goals, including minimisation of glucocorticoid use.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Fanouriakis A, Tziolos N, Bertsias G, et al. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2020. PMID: 33051219. doi:10.1136/annrheumdis-2020-218272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。